Literature DB >> 1570298

Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals.

M Algiman1, G Dietrich, U E Nydegger, D Boieldieu, Y Sultan, M D Kazatchkine.   

Abstract

Spontaneous inhibitors of factor VIII (FVIII) are pathogenic IgG autoantibodies of restricted isotypic heterogeneity found in the plasma of patients presenting with bleeding episodes and low levels of FVIII. We now report the presence of a natural FVIII-neutralizing activity in 85 of 500 plasma samples (17%) from healthy donors. FVIII-inhibitory activity was present in F(ab')2 fragments of purified IgG and was dose-dependent. The titer of anti-FVIII antibodies in normal plasma ranged between 0.4 (threshold of detection) and 2.0 Bethesda units. Anti-FVIII IgG was also detected in normal plasma by using an ELISA. Anti-FVIII antibodies from healthy individuals did not exhibit restricted isotypic heterogeneity. Mean levels of FVIII activity did not differ significantly between individuals with and without detectable anti-FVIII antibodies in plasma. Natural anti-FVIII IgG inhibited FVIII activity in pools of normal plasma and in plasma of certain donors in the pool but did not inhibit FVIII activity in autologous plasma. These observations demonstrate that polyclonal IgG antibodies against procoagulant FVIII are present in healthy individuals. The antibodies are natural IgG autoantibodies and/or antibodies directed against epitopes associated with a so far unidentified allotypic polymorphism of the human FVIII molecule.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1570298      PMCID: PMC525577          DOI: 10.1073/pnas.89.9.3795

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  11 in total

Review 1.  Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'.

Authors:  S Avrameas
Journal:  Immunol Today       Date:  1991-05

2.  Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies.

Authors:  G Dietrich; M D Kazatchkine
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

3.  Identification of a F.VIII epitope recognized by a human hemophilic inhibitor.

Authors:  B C Lubahn; J Ware; D W Stafford; H M Reisner
Journal:  Blood       Date:  1989-02       Impact factor: 22.113

4.  Antibodies to factor VIII. I. Variations in stability of antigen-antibody complexes in hemophilia A.

Authors:  J P Allain; D Frommel
Journal:  Blood       Date:  1973-09       Impact factor: 22.113

5.  Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

Authors:  Y Sultan; M D Kazatchkine; P Maisonneuve; U E Nydegger
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

6.  Factor VIII levels and blood group antigens.

Authors:  C J McCallum; I R Peake; R G Newcombe; A L Bloom
Journal:  Thromb Haemost       Date:  1983-10-31       Impact factor: 5.249

7.  Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization.

Authors:  D Scandella; M Mattingly; S de Graaf; C A Fulcher
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

8.  Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig.

Authors:  F Rossi; M D Kazatchkine
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

9.  Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies.

Authors:  Y Sultan; F Rossi; M D Kazatchkine
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

10.  Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain.

Authors:  P A Foster; C A Fulcher; R A Houghten; S de Graaf Mahoney; T S Zimmerman
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

View more
  17 in total

1.  IgG Antibodies Against Factor VIII in Normal Individuals.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.

Authors:  J G Gilles; J M Saint-Remy
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

3.  Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance.

Authors:  C H Miller; S J Platt; A S Rice; F Kelly; J M Soucie
Journal:  J Thromb Haemost       Date:  2012-06       Impact factor: 5.824

4.  CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells.

Authors:  Sylvain Meunier; Catherine Menier; Elodie Marcon; Sébastien Lacroix-Desmazes; Bernard Maillère
Journal:  Blood Adv       Date:  2017-09-25

5.  Invariance and restriction toward a limited set of self-antigens characterize neonatal IgM antibody repertoires and prevail in autoreactive repertoires of healthy adults.

Authors:  L Mouthon; A Nobrega; N Nicolas; S V Kaveri; C Barreau; A Coutinho; M D Kazatchkine
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

6.  Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin.

Authors:  T L Ortel; M C Mercer; E H Thames; K D Moore; J H Lawson
Journal:  Ann Surg       Date:  2001-01       Impact factor: 12.969

Review 7.  Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies.

Authors:  Géraldine Lavigne-Lissalde; Chantal Rothschild; Claire Pouplard; Priscilla Lapalud; Yves Gruel; Jean-François Schved; Claude Granier
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

8.  Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.

Authors:  J Batlle; E Gómez; E Rendal; J Torea; E Lourés; M Couselo; P Vila; C Sedano; X Tusell; M Magallón; M Quintana; R González-Boullosa; M F López-Fernández
Journal:  Ann Hematol       Date:  1996-05       Impact factor: 3.673

Review 9.  Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia

Authors:  Richard S Blumberg; David Lillicrap
Journal:  Blood       Date:  2018-03-27       Impact factor: 22.113

10.  Acquired haemophilia A after stem cell transplant for sickle cell disease: treatment with recombinant porcine factor VIII (OBI-1) and tolerance induction with rituximab/prednisone.

Authors:  J N Lozier; K Nghiem; M Lee; B Hodsdon; G Joe; R P Weitzel; J F Tisdale; M Hsieh
Journal:  Haemophilia       Date:  2014-03       Impact factor: 4.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.